{
    "nct_id": "NCT03180294",
    "official_title": "Phase II Double Blind Dose Finding Trial of Bupropion Versus Placebo for Sexual Desire in Women With Breast or Gynecologic Cancer",
    "inclusion_criteria": "* PRIOR TO STEP 1 REGISTRATION\n* Score of < 9 on the PHQ-4\n* Patients must have a FSFI desire subscale baseline score less than 3.3\n\n  * NOTE-Both the PHQ-4 and FSFI must be completed by the patient and data entered in Oncology Patient Enrollment Network (OPEN) at Step 1 registration to determine eligibility\n* Diagnosis of breast or gynecologic cancer [examples are lobular carcinoma in situ (LCIS),ductal carcinoma in situ (DCIS), invasive breast, ovarian, endometrial, vulvar, cervical and vaginal]\n* Completed definitive therapy consisting of surgery, chemotherapy or radiation therapy at least 180 days ago (may continue on Herceptin or endocrine therapy)\n* Post menopausal as defined by at least ONE of the following:\n\n  * 12 months (365 days) without a period;\n  * Bilateral oophorectomy;\n  * Chemically induced menopause as long as there are no plans to stop during the study;\n  * For women 57 and under, if at least one ovary and woman has had hysterectomy, must have follicle stimulating hormone (FSH) (> 30 mIU/mL) and estradiol in menopausal range per institution?s laboratory (< 10 for ultra sensitive assay: < 25-30 otherwise);\n  * At least one ovary intact and 180 days without a period with FSH (> 30 mIU/mL) and estradiol in menopausal range per institution's laboratory (< 10 for ultra sensitive assay: < 25-30 otherwise); Note: Women 58 and older do not have to have hormonal tests.\n* History, physical and performance status of 2 or less within 180 days prior to registration\n* Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN)\n* Total bilirubin =< 1.5 x ULN\n* Glomerular filtration rate > 90ml/min\n* For breast cancer patients only, endocrine therapies are allowed (such as aromatase inhibitors, but not current tamoxifen. Prior tamoxifen is permitted with a 30 day wash out period). )\n* Vaginal estrogen is allowed, for all protocol disease sites, if dose equal to or less than that in estring (< 7.5 mcg) and it has been used for at least 30 days with no plans to stop or alter use during the course of the study\n* Antidepressants for mood and hot flashes, including selective serotonin reuptake inhibitors (SSRIs) will be allowed if patients have been on a stable dose for the last 60 days and the dose is not expected to change during the course of the study; only subthreshold or low dose antidepressants will be allowed (e.g. Effexor up to 75 mg or Lexapro 5-10 mg or Celexa 10- 20 mg)\n* The patient must provide study-specific informed consent prior to study entry/screening\n* Women who report that their motivation/desire for sexual intimacy has decreased since her cancer diagnosis\n* Able to swallow whole capsules\n* Proficient in English (due to number of questionnaires not validated in other languages)\n* Completion of the FSFI and PHQ-4; both questionnaires will be required and data entered at the time of step 1 registration\n* PRIOR TO STEP 2 RANDOMIZATION\n* Completion of the following baseline quality of life forms: PHQ-4, FSFI, PROMIS sexual function and satisfaction, PROMIS fatigue short form 8a, Impact of Treatment Scale, patient reported outcomes (PRO)-Common Terminology Criteria for Adverse Events (CTCAE) items, and revised dyadic adjustment scale; these quality of life forms will be required and data must be entered in Medidata Rave at step 2 registration; if available at the time of step 1 registration, step 2 registration can take place immediately after step 1; women who do not currently have a partner do not have to complete the revised dyadic adjustment scale; enter \"no partner\" for this form\nHealthy volunteers allowed\nMust be FEMALE\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Untreated depression, major depressive disorder (MDD), suicidal ideations or anxiety disorders in the past 5 years per the medical chart based on Diagnostic and Statistical Manual (DSM) IV diagnoses\n* Seizure disorders\n* Current or history of anorexia or bulimia in the past 5 years\n* Allergy to bupropion\n* Use of drugs metabolized by CYP2D6\n* Stage IV cancer\n* History of Parkinson's disease, multiple sclerosis or fibromyalgia\n* Extensive pelvic exenteration surgery, surgeries which include partial or total vaginectomy with or without reconstruction; radical vulvectomy with or without remove of clitoris\n* Women who are currently undergoing or planning to undergo reconstruction surgery during the course of the study; women who have completed reconstruction surgery must be 30 days from surgery\n* Oral or transdermal estrogen therapy is not allowed\n* Males are not permitted to participate\n* Patients undergoing abrupt discontinuation of alcohol, benzodiazepines, barbiturates, and antiepileptic drugs after chronic use\n* Patients who discontinue monoamine oxidase (MAO)-inhibitor (I)'s within 14 days prior to starting the investigational drug\n* Poorly controlled hypertension (systolic blood pressure [BP] >= 160 mmHg or diastolic BP >= 100 mmHg) on three or more readings in the past 12 months\n* Patients with active bipolar disorder\n* Patients with impaired decision making as determined by the treating physician\n* Concurrent use of bupropion\n* Concomitant invasive malignancy requiring treatment other than non-melanomatous skin cancer.\n* Previous or concurrent use of flibanserin.",
    "miscellaneous_criteria": ""
}